Table 3. Clinical outcomes of commonly used second-line anticancer agents as compared with γδ T-cell immunotherapy.*.

Disease	Second-line treatments	CR		PR		SD		PD
				%	95% CI	%	95% CI	%	95% CI	%	95% CI
Advanced prostate cancer48	Prednisolone + docetaxel (n = 101, 3 randomized controlled trials)	0	0	25.2	8.4–41.8	44.43	32–56.8	30.40	14.5–46.2
	In-vivo expansion of γδT cells (n = 12, 6 missing)	0		33.3		41.6		25.0
Advanced renal cell carcinoma52	Everolimus (n = 277, 1 randomized phase 3 study)	0	0	1.8	-	66.5	-	31.7	-
	Adoptive transfer of γδT cells (n = 21, 7 missing)	4.8		0	0	42.9		52.4
	In-vivo expansion of γδT cells (n = 15, 4 missing)	0	0	0	0	66.7		33.3
Advanced NSCLC53,54	Erlotinib (n = 3324, 2 randomized controlled trials)	0.4	0.17–0.73	7.2	1.88–10.89	33.9	4.9–43.4	58.5	6.9–72.1
	Docetaxel (n = 385, 2 randomized controlled trials)	2.6	0.3–4.9	9.6	8.9–10.2	37.7	30.0–45.3	50.2	45.5–55.0
	Adoptive transfer of γδT cells (n = 24, 1 missing)	0		0		54.2		45.8

^*Data are pooled from clinical trials and standard of care treatments were selected based upon current UK or US guidelines for treatment of the tumors in question. A more detailed breakdown of γδT cell immunotherapy results is included in Table S2. CI, confidence interval; CR, complete response; NSCLC, non-small cell lung carcinoma; PD, progressive disease; PR, partial response; SD, stable disease.